Novartis Pelacarsen Miss Shifts the Weight to Amgen and Lilly

Novartis said Friday that its Phase 3 outcomes trial of pelacarsen, a lipoprotein(a)-lowering drug, failed to beat its comparator, making the Swiss drugmaker the third large pharmaceutical company in two months to report a major cardiovascular outcomes trial failure and raising the stakes for Amgen's and Eli Lilly's rival Lp(a) programs.

Novartis said Friday that its Phase 3 study of pelacarsen missed, with the drug proving no better than its comparator on the trial's cardiovascular outcome. The result closes out one of the most closely watched bets in cardiology: that lowering lipoprotein(a), a genetically determined blood particle long linked to heart attacks and strokes, would translate into fewer of those events in patients.

It also extends an unusually bad run for the field. As Endpoints News reported, Novartis is the third large drugmaker in two months to report a failed cardiovascular outcomes trial, following misses at Novo Nordisk and AstraZeneca. Three swings, three strikes, in a category where trials cost hundreds of millions and take years to read out.

Why Lp(a) mattered so much to cardiologists

Lipoprotein(a) — usually written Lp(a) — is a cholesterol-carrying particle whose level in the blood is set almost entirely by inheritance. Diet does not move it. Statins do not meaningfully move it. Large population studies have tied high Lp(a) to elevated cardiovascular risk, and that observation created one of the cleanest-looking drug hypotheses in modern cardiology: build a molecule that shuts down production of the particle, drive levels down sharply, and watch events fall.

Pelacarsen was the furthest advanced test of that idea. An antisense therapy designed to silence the gene that produces the protein backbone of Lp(a), it was the first of the class to reach a full cardiovascular outcomes readout — the kind of trial that counts heart attacks, strokes and cardiovascular deaths rather than a laboratory number. Missing that endpoint does not automatically mean the underlying biology is wrong, but it removes the field's most convenient proof point and forces every subsequent program to argue its case from scratch.

The immediate questions that will occupy cardiologists once full data are presented: whether the patients enrolled were high-risk enough, whether follow-up was long enough for a genetically driven risk factor to show a treatment benefit, and whether the depth of Lp(a) reduction achieved was sufficient. Until Novartis puts the detailed dataset in front of a medical meeting, those remain open.

What the miss loads onto Amgen and Lilly

Two rival programs now carry the weight of the hypothesis. Amgen (AMGN) has olpasiran, and Eli Lilly (LLY) has lepodisiran — both small interfering RNA drugs, a different mechanism from pelacarsen's antisense approach but aimed at the same target with the same commercial logic behind them.

The read-through is genuinely ambiguous, which is why the reaction has been measured rather than violent. The bear case is straightforward: if the most advanced Lp(a)-lowering agent could not beat its comparator on hard cardiovascular outcomes, the target itself may not deliver the benefit the epidemiology implied, and two more expensive outcomes trials are running toward the same wall.

The bull case is that mechanism and magnitude matter. siRNA drugs are dosed less frequently and, in the Lp(a) field, have shown deeper and more durable suppression than antisense in earlier-stage work — the argument being that pelacarsen may simply not have pushed levels down far enough, for long enough, in the right patients. That argument only gets settled by data, and the data arrive on the trials' own timetables, not the market's.

Either way, the cost of being wrong has gone up. Outcomes trials in cardiovascular disease are among the most expensive assets in a pipeline, and a sponsor deciding whether to expand enrollment, extend follow-up or hold the line now does so knowing that the field's first full answer was negative.

How the shares closed on the day of the readout

Trading was closed at the time of writing. As of the last trade on Friday, 4 September 2026 at 20:00 GMT, Novartis (NVS) finished at 160.02, down 1.88% from a previous close of 163.09, having ranged between 159.63 and 160.93 on the day — a decline of about 3.07 points on the session.

The read-through names moved in the same direction but less sharply. Amgen closed at 437.27, off 1.54% from 444.12, with a day range of 435.00 to 441.85. Eli Lilly ended at 1,149.40, down 0.88% from 1,159.60, and traded as low as 1,138.31 and as high as 1,158.44 — the widest intraday swing of the group relative to its close, and a fair marker of how unsettled the read-through question is.

The two companies whose own cardiovascular misses preceded this one also finished lower. Novo Nordisk (NVO) closed at 46.61, down 1.89% from 47.51, and AstraZeneca (AZN) at 162.73, down 1.24% from 164.77.

Context matters here: the broad market was soft the same session. The S&P 500 tracker (SPY) closed at $770.23, down 0.38%, and the Dow tracker (DIA) at $534.12, down 0.52%, while the Nasdaq 100 tracker (QQQ) edged up 0.19% to $719.00. Against that backdrop the drug names underperformed, but none of the moves is the sort of gap that follows a company-defining pipeline loss — a reminder that pelacarsen was a call option on a new market rather than a load-bearing part of anyone's current earnings.

The pattern three failures make

Taken individually, each of the three misses of the past two months has its own explanation. Taken together, they say something less comfortable about the economics of cardiovascular drug development. The bar set by existing therapy — statins, and on top of them the LDL-lowering drugs already in wide use — is high. Trials must therefore run larger and longer to detect an incremental benefit, which raises the capital at risk and narrows the window in which a winner can earn it back before patent expiry.

That has consequences beyond the three companies named. Biotechs with early-stage Lp(a) or broader cardiometabolic assets will find partnering conversations harder, and licensing terms will reflect a target whose first outcomes verdict came back negative. Investors who had been treating Lp(a) as a probable multi-billion-dollar category will now discount it toward the more skeptical end.

What to watch from here

• Full pelacarsen data at a medical meeting: enrolled population, degree of Lp(a) lowering achieved, duration of follow-up, and any prespecified subgroup where a signal appeared.
• Whether Amgen or Eli Lilly comments on trial design or timelines for olpasiran and lepodisiran in the wake of the readout.
• Any change in how Novartis frames the asset — continued development in a narrower population versus discontinuation.
• Whether the three consecutive misses reshape how large drugmakers size and stage cardiovascular outcomes trials generally.

None of that resolves quickly. The Lp(a) thesis is not dead on one trial, but it is now a hypothesis that has to be proven rather than assumed — and the two companies holding the remaining tickets are the ones the market will price against it.

Key facts

• NVS last close: 160.02, -1.88%, as of Fri 4 Sep 2026 20:00 GMT
• AMGN last close: 437.27, -1.54%, same session
• LLY last close: 1,149.40, -0.88%, same session
• CV outcomes failures: Third at a major drugmaker in two months, after Novo Nordisk and AstraZeneca

Frequently asked questions

What did Novartis report about pelacarsen?

Novartis said on Friday that its Phase 3 study of pelacarsen missed, with the drug performing no better than its comparator on the trial's cardiovascular outcome. Pelacarsen was the most advanced drug designed to lower lipoprotein(a), and this was the first full cardiovascular outcomes readout for that class of therapy.

What is lipoprotein(a) and why do drugmakers target it?

Lipoprotein(a), or Lp(a), is a cholesterol-carrying particle in the blood whose level is set largely by inheritance and is not meaningfully lowered by diet or statins. Population studies have linked high Lp(a) to greater risk of heart attack and stroke, which made it an attractive target for drugs designed to suppress its production.

Which competing programs are affected?

Amgen's olpasiran and Eli Lilly's lepodisiran are the two most advanced remaining Lp(a)-lowering candidates. Both are small interfering RNA drugs, a different mechanism from pelacarsen's antisense approach, but they target the same biology, so a negative outcomes result for pelacarsen raises the stakes for both programs.

How did the shares react?

As of the last trade on Friday, 4 September 2026 at 20:00 GMT, Novartis closed at 160.02, down 1.88%. Amgen finished at 437.27, down 1.54%, and Eli Lilly at 1,149.40, down 0.88%. The broad market was also soft that session, with the S&P 500 tracker down 0.38%.

Does this mean the Lp(a) hypothesis is dead?

Not necessarily. A single negative outcomes trial can reflect the patient population enrolled, the length of follow-up, or how deeply the drug lowered Lp(a), rather than a flaw in the underlying biology. But it removes the field's most advanced proof point, and remaining programs now have to prove the case rather than assume it.

Which other companies had cardiovascular trial failures recently?

Novo Nordisk and AstraZeneca both reported major cardiovascular outcomes trial failures in the two months before the Novartis result, making pelacarsen the third such miss at a large drugmaker over that stretch. Both companies' shares also closed lower on the same session as the Novartis announcement.

Sources

• Novartis' Phase 3 pelacarsen study miss raises the stakes for Amgen, Lilly — Endpoints News

Photo: https://kaboompics.com/ · Pexels Licence — source